Of note, Marfella et al. found that patients with COVID-19 who had hyperglycemia at admission had five-fold higher plasma IL-6 levels than non-hyperglycemia cases, and hyperglycemia diminished the effect of tocilizumab on disease progression, possibly through the upregulation of IL-6 (Marfella et al., 2020; Sardu et al., 2020a; Sardu et al., 2020b). This evidence concerns the gene IL6 and COVID-19.